Farallon Capital Management Reduces $123M in Tango Therapeutics, Inc. ($TNGX)
Key Points
- Farallon Capital Management changed its Tango Therapeutics, Inc. ($TNGX) stake by 30.3% last quarter, cutting to 9,097,411 shares worth $281.47 million.
- Wall Street's consensus rating on $TNGX is Strong Buy and an average price target of $40.45.
- $TNGX last traded around $30.94.
Farallon Capital Management reduced its position in Tango Therapeutics, Inc. ($TNGX) by 30.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,097,411 shares of Tango Therapeutics, Inc. after selling 3,964,000 shares during the quarter. Farallon Capital Management's holdings in Tango Therapeutics, Inc. were worth $281.47 million as of its most recent filing.
Tango Therapeutics, Inc. ($TNGX) Stock
Tango Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.